Most catalogues describe a fraction of what a cell processing operation can actually do, which is why the useful question is rarely whether something is on the list. It is whether the population you want can be isolated to a standard that will hold up, in the quantity you need, from a donor you can specify. Those three constraints interact, and the interaction is what determines the answer.
What makes a population easy or hard
Three properties govern almost every custom isolation conversation. Frequency, because a population that represents a small fraction of the starting material requires a great deal more input to reach a useful yield. Marker quality, because a population defined by a single bright surface marker is straightforward while one requiring a combination of positive and negative markers is not. And robustness, because some cells tolerate the physical handling of isolation better than others.
| Property | Easier | Harder |
|---|---|---|
| Frequency in source | Abundant, percent-level | Rare, fractions of a percent |
| Marker definition | Single distinctive surface marker | Multi-parameter, or requiring negative selection against several |
| Handling tolerance | Tolerant of columns and washes | Fragile, or activated by the isolation itself |
| Downstream requirement | Phenotype only | Function preserved after isolation |
A request combining the harder column across all four rows is not impossible, but it is a development exercise rather than an order, and it should be scoped as one.
Positive and negative selection are not interchangeable
Positive selection targets the cells you want and generally gives higher purity. The cost is that something has bound the surface of the cells you intend to use, which for a receptor involved in activation may not be neutral.
Negative selection removes everything else, leaving the target untouched. Purity is typically lower and more input is required, and the trade is worth making whenever downstream function matters more than the last few percentage points of purity. Which of these a supplier defaults to is worth asking, because it is frequently unstated and it changes what you receive.
Quantity is a constraint, not a preference
For rare populations, the amount of starting material required scales with how rare the target is, and eventually the requirement exceeds what a single donor can provide. At that point the choice is between accepting less material, pooling donors and losing donor identity, or scheduling multiple collections from the same donor.
The third option only exists where a repeat-collection program does. This is one of several places where donor recall stops being a procurement nicety and becomes the thing that determines feasibility, as discussed in recallable donors.
What to bring to the conversation
A scoped request answers faster and more accurately than an open one. Bring the population defined by markers rather than by name, since names are used inconsistently. Bring the quantity you need and whether that is per experiment or in total. Bring the donor criteria that are genuine constraints. Bring the downstream application, because it determines whether function has to be preserved. Bring the grade. And bring the timeline, since a development exercise and a catalogue order have very different lead times.
Where the honest answer is no
Some requests should be declined rather than attempted. A population too rare to yield useful numbers from available material. A purity requirement the marker definition cannot support. A functional requirement incompatible with the isolation method needed to reach the purity. A supplier who agrees to all of these without qualification is describing an ambition rather than a capability, and the discovery happens later at your expense.
OrganaBio documents isolated populations including pan T cells, NK cells and cord blood CD34+ HSCs, alongside whole leukopaks in whole, half, quarter and custom formats for programs isolating in house. Custom scoping is handled with the scientific team rather than promised from a catalogue.
Frequently asked questions
What determines whether a cell population can be custom isolated?
Frequency in the source material, how cleanly the population is defined by surface markers, how well those cells tolerate the physical handling of isolation, and whether function has to be preserved afterwards. A request that is difficult on all four is a development exercise rather than an order.
What is the difference between positive and negative selection?
Positive selection targets the cells you want and usually achieves higher purity, but something has bound the surface of the cells you intend to use. Negative selection removes everything else and leaves the target untouched, typically at lower purity and higher input requirement.
Which selection method should I ask for?
Negative selection where downstream function matters more than the last few percentage points of purity, positive selection where purity dominates. Ask which a supplier defaults to, because it is frequently unstated and it changes what you receive.
Why are rare populations harder to obtain in quantity?
The starting material required scales with how rare the target is, and eventually exceeds what one donor can provide. The options then are less material, pooling donors and losing donor identity, or scheduling multiple collections from the same donor where a recall program exists.
How should I define a custom isolation request?
By surface markers rather than by population name, since names are used inconsistently. Include quantity and whether it is per experiment or total, genuine donor constraints, the downstream application, the grade, and the timeline.
Should a supplier ever decline a custom request?
Yes. A population too rare to yield useful numbers, a purity requirement the marker definition cannot support, or a functional requirement incompatible with the necessary isolation method should all be declined. A supplier agreeing to everything without qualification is describing ambition rather than capability.
Can I isolate the population myself instead?
Often, and it makes sense when the isolation is part of what you are studying or when a downstream step is sensitive to how it was done. Whole, half, quarter and custom leukopak formats exist for exactly that.
Working through this on a live program?
The scientific team works through sourcing and specification questions with cell therapy and research groups directly, including donor characterization, format selection and documentation scope.
